Imatinib blocks many protein kinases, including fusion proteins BCR-ABL and KIT, and has been approved for the treatment of chronic myelogenous leukaemia and gastrointestinal stromal tumours. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.